Adaptimmune Therapeutics
Stock Forecast, Prediction & Price Target
Adaptimmune Therapeutics Financial Estimates
Adaptimmune Therapeutics Revenue Estimates
Adaptimmune Therapeutics EBITDA Estimates
Adaptimmune Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $6.14M N/A | $27.14M 341.50% | $60.28M 122.04% | Avg: $49.13M Low: $44.85M High: $53.41M avg. -18.48% | Avg: $61.06M Low: $32.42M High: $95.91M avg. 24.26% | Avg: $100.82M Low: $53.54M High: $158.37M avg. 65.12% | Avg: $169.45M Low: $89.99M High: $266.16M avg. 68.06% |
Net Income
% change YoY
| $-158.09M N/A | $-165.45M -4.65% | $-113.87M 31.17% | Avg: $-168.56M Low: $-160.85M High: $-48.25M avg. -48.03% | Avg: $-178.74M Low: $-262.70M High: $-58.87M avg. -6.03% | Avg: $-134.60M Low: $-234.48M High: $-52.54M avg. 24.69% | Avg: $-135.72M Low: $-236.43M High: $-52.98M avg. -0.83% |
EBITDA
% change YoY
| $-155.67M N/A | $-157.89M -1.42% | $-128.19M 18.80% | Avg: $-49.13M Low: $-53.41M High: $-44.85M avg. 61.67% | Avg: $-61.06M Low: $-95.91M High: $-32.42M avg. -24.26% | Avg: $-100.82M Low: $-158.37M High: $-53.54M avg. -65.12% | Avg: $-169.45M Low: $-266.16M High: $-89.99M avg. -68.06% |
EPS
% change YoY
| -$1.01 N/A | -$1.03 -1.98% | -$0.57 44.66% | Avg: -$0.56 Low: -$0.8 High: -$0.24 avg. 1.75% | Avg: -$0.75 Low: -$1.31 High: -$0.29 avg. -33.92% | Avg: -$0.67 Low: -$1.17 High: -$0.26 avg. 10.74% | Avg: -$0.68 Low: -$1.18 High: -$0.26 avg. -0.83% |
Operating Expenses
% change YoY
| $168.39M N/A | $191.11M 13.49% | $200.02M 4.66% | Avg: $615.73M Low: $562.08M High: $669.39M avg. 207.83% | Avg: $765.13M Low: $406.34M High: $1.20B avg. 24.26% | Avg: $1.26B Low: $670.97M High: $1.98B avg. 65.12% | Avg: $2.12B Low: $1.12B High: $3.33B avg. 68.06% |
FAQ
What is Adaptimmune Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -7.55% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -160.85M, average is -168.56M and high is -48.25M.
What is Adaptimmune Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 34.74% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $44.85M, average is $49.13M and high is $53.41M.
What is Adaptimmune Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -5.56% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.8, average is -$0.56 and high is $-0.24.
What is the best performing analyst?
In the last twelve months analysts have been covering Adaptimmune Therapeutics stock. The most successful analyst is George Farmer.